ACC preview: a veri important test for Merck and Bayer
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
Asco-GU 2020: revving up for Peloton deal validation
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
Ash 2019 winners and losers
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
SABCS 2019 – Tecentriq stumbles in triple negative disease
Disappointing data in a small neoadjuvant trial testing Tecentriq in triple negative breast cancer suggests that once again Keytruda may have an edge.
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.
Ash 2019 – Regeneron takes the bispecific baton and runs
Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.
Ash 2019 – Merck gets Arqule ahead of data
Arqule’s investors have done pretty nicely out of today’s buyout by Merck & Co, but might be wondering whether they could have done better still.
Ash 2019 – for Car-T the bispecific antibody threat is real
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
Ash 2019 – former Celgene holders look anxiously at contingent value
Celgene CVR holders have been desperate to find out whether JCAR017 is approvable. Yesterday at Ash they got their answer... kind of.
